- WKN: 609500
- ISIN: DE0006095003
- Land: Deutschland
Nachricht vom 21.10.2021 | 07:00
ENCAVIS AG acquires solar park Groß Behnitz (25 MWp) of the project pipeline of its strategic development partner Sunovis
DGAP-News: ENCAVIS AG
/ Key word(s): Acquisition/Expansion
ENCAVIS acquires solar park Groß Behnitz (25 MWp) of the project pipeline of its strategic development partner Sunovis
"With the PV park Groß Behnitz we realise the first project of our more than 200 MW+ strategic development pipeline of PPA solar power plant projects with Sunovis", welcomes Dr Dierk Paskert, CEO of Encavis AG, the start of the ongoing cooperation. Sunovis acts in Groß Behnitz as developer, EPC partner in the current construction phase and is responsible for the operational and maintenance (O&M) services.
Encavis is a signatory of the UN Global Compact as well as of the UN PRI network. Encavis AG's environmental, social and governance performance has been awarded by two of the world's leading ESG rating agencies. MSCI ESG Ratings awarded the corporate ESG performance with "AA" and ISS ESG with their "Prime" label.
Additional information can be found on www.encavis.com
|Große Elbstraße 59|
|Phone:||+49 4037 85 62 -0|
|Fax:||+49 4037 85 62 -129|
|Listed:||Regulated Market in Frankfurt (Prime Standard), Hamburg; Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1242356|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
30. November 15:30 Buffetts Milliarden-Wette: Nubank-IPO kleiner als erwartet
30. November 16:04 Deutsche Telekom: Droht hier ein neues Problem?
30. November 16:17 Global Fashion Group: Aktie mit Grusel-Chart – gibt es noch Hoffnung?
30. November 16:22 Die Nel-Aktie? Ein Kauf!
30. November 17:25 DAX: Powell und Omikron sorgen für kräftigen Gegenwind
News im Fokus
Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben
30. November 2021, 16:02
Capital Markets Day
08. Dezember 2021
Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy
30. November 2021